S100 proteins as therapeutic targets
- 145 Downloads
The human genome codes for 21 S100 protein family members, which exhibit cell- and tissue-specific expression patterns. Despite sharing a high degree of sequence and structural similarity, the S100 proteins bind a diverse range of protein targets and contribute to a broad array of intracellular and extracellular functions. Consequently, the S100 proteins regulate multiple cellular processes such as proliferation, migration and/or invasion, and differentiation, and play important roles in a variety of cancers, autoimmune diseases, and chronic inflammatory disorders. This review focuses on the development of S100 neutralizing antibodies and small molecule inhibitors and their potential therapeutic use in controlling disease progression and severity.
KeywordsS100 protein Calcium binding Small molecule inhibitor Neutralizing antibody
We thank Drs. SC Almo and JM Backer (Albert Einstein College of Medicine) for helpful discussions and for reading the manuscript. This work was supported by National Institutes of Health grants P01 CA100324 and R01 GM119279.
Compliance with ethical standards
Conflict of interest
Anne R. Bresnick declares that she has no conflict of interest.
This article does not contain any studies with human participants or animals performed by the author.
- Ambartsumian NS et al (1996) Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 13:1621–1630Google Scholar
- Brem B et al. (2017) Novel thiazolo[5,4-b]phenothiazine derivatives: synthesis, structural characterization, and in vitro evaluation of antiproliferative activity against human leukaemia. Int J Mol Sci 18 doi: https://doi.org/10.3390/ijms18071365
- Burock S, Daum S, Keilholz U, Neumann K, Walther W, Stein U (2018) Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO tria. BMC Cancer 18:297. https://doi.org/10.1186/s12885-018-4197-9 PubMedCentralCrossRefPubMedGoogle Scholar
- Cunden LS, Brophy MB, Rodriguez GE, Flaxman HA, Nolan EM (2017) Biochemical and functional evaluation of the intramolecular disulfide bonds in the zinc-chelating antimicrobial protein human S100A7 (Psoriasin). Biochemistry 56:5726–5738. https://doi.org/10.1021/acs.biochem.7b00781 PubMedCentralCrossRefPubMedGoogle Scholar
- Cunningham MF, Docherty NG, Burke JP, O'Connell PR (2010) S100A4 expression is increased in stricture fibroblasts from patients with fibrostenosing Crohn’s disease and promotes intestinal fibroblast migration. Am J Physiol Gastrointest Liver Physiol 299:G457–G466. https://doi.org/10.1152/ajpgi.00351.2009 CrossRefPubMedGoogle Scholar
- Dahlmann M, Kobelt D, Walther W, Mudduluru G, Stein U (2016) S100A4 in cancer metastasis: Wnt signaling-driven interventions for metastasis restriction cancers (Basel) 8 doi: https://doi.org/10.3390/cancers8060059
- Fizazi K et al (2017) A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Ann Oncol 28:2741–2746. https://doi.org/10.1093/annonc/mdx487 PubMedCentralCrossRefPubMedGoogle Scholar
- Gao H et al. (2018) S100B suppression alters polarization of infiltrating myeloid-derived cells in gliomas and inhibits tumor growth Cancer Lett doi: https://doi.org/10.1016/j.canlet.2018.07.034
- Goldstein DA (1990) Serum calcium. In: rd, Walker HK, Hall WD, Hurst JW (eds) Clinical methods: the history, physical, and laboratory examinations. Boston,Google Scholar
- Grum-Schwensen B, Klingelhofer J, Berg CH, El-Naaman C, Grigorian M, Lukanidin E, Ambartsumian N (2005) Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 65:3772–3780. https://doi.org/10.1158/0008-5472.CAN-04-4510 CrossRefPubMedGoogle Scholar
- Kessel C et al. (2018) Calcium and zinc tune autoinflammatory Toll-like receptor 4 signaling by S100A12. J Allergy Clin Immunol doi: https://doi.org/10.1016/j.jaci.2018.06.027
- Kiss B, Duelli A, Radnai L, Kekesi KA, Katona G, Nyitray L (2012) Crystal structure of the S100A4-nonmuscle myosin IIA tail fragment complex reveals an asymmetric target binding mechanism. Proc Natl Acad Sci U S A 109:6048–6053. https://doi.org/10.1073/pnas.1114732109 PubMedCentralCrossRefPubMedGoogle Scholar
- Leclerc E, Heizmann CW (2011) The importance of Ca2+/Zn2+ signaling S100 proteins and RAGE in translational medicine. Front Biosci (Schol Ed) 3:1232–1262Google Scholar
- Lenarcic Zivkovic M, Zareba-Koziol M, Zhukova L, Poznanski J, Zhukov I, Wyslouch-Cieszynska A (2012) Post-translational S-nitrosylation is an endogenous factor fine tuning the properties of human S100A1 protein. J Biol Chem 287:40457–40470. https://doi.org/10.1074/jbc.M112.418392 PubMedCentralCrossRefPubMedGoogle Scholar
- Liriano MA, Varney KM, Wright NT, Hoffman CL, Toth EA, Ishima R, Weber DJ (2012) Target binding to S100B reduces dynamic properties and increases Ca(2+)-binding affinity for wild type and EF-hand mutant proteins. J Mol Biol 423:365–385. https://doi.org/10.1016/j.jmb.2012.07.011 PubMedCentralCrossRefPubMedGoogle Scholar
- Maelandsmo GM et al (1996) Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 56:5490–5498Google Scholar
- Park H, Adsit FG, Boyington JC (2010) The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem 285:40762–40770. https://doi.org/10.1074/jbc.M110.169276 PubMedCentralCrossRefPubMedGoogle Scholar
- Pili R et al (2011) Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29:4022–4028. https://doi.org/10.1200/JCO.2011.35.6295 CrossRefGoogle Scholar
- Pluta K, Jelen M, Morak-Mlodawska B, Zimecki M, Artym J, Kocieba M, Zaczynska E (2017) Azaphenothiazines - promising phenothiazine derivatives. An insight into nomenclature, synthesis, structure elucidation and biological properties. Eur J Med Chem 138:774–806. https://doi.org/10.1016/j.ejmech.2017.07.009 CrossRefPubMedGoogle Scholar
- Reddy TR, Li C, Fischer PM, Dekker LV (2012) Three-dimensional pharmacophore design and biochemical screening identifies substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interaction. ChemMedChem 7:1435–1446. https://doi.org/10.1002/cmdc.201200107 PubMedCentralCrossRefPubMedGoogle Scholar
- Reddy TR, Li C, Guo X, Myrvang HK, Fischer PM, Dekker LV (2011) Design, synthesis, and structure-activity relationship exploration of 1-substituted 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one analogues as inhibitors of the annexin A2-S100A10 protein interaction. J Med Chem 54:2080–2094. https://doi.org/10.1021/jm101212e PubMedCentralCrossRefPubMedGoogle Scholar
- Vogt A, McDonald PR, Tamewitz A, Sikorski RP, Wipf P, Skoko JJ 3rd, Lazo JS (2008) A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther 7:330–340. https://doi.org/10.1158/1535-7163.MCT-07-2165 CrossRefPubMedGoogle Scholar
- Xie J, Burz DS, He W, Bronstein IB, Lednev I, Shekhtman A (2007) Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 282:4218–4231. https://doi.org/10.1074/jbc.M608888200 CrossRefGoogle Scholar
- Xue C, Plieth D, Venkov C, Xu C, Neilson EG (2003) The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63:3386–3394Google Scholar